Overview of studies
Table 1. All studies that are approved by the IPCI governance board (updated quarterly)
|2015-03||Gout in general practice; risk factors and treatment.||In this study, risk factors for gout and the frequency of gout attacks are investigated. It is investigated whether the presentation of gout is an indicator of renal or cardiovascular morbidity in the future, and whether maintenance treatment with allopurinol actually reduces the frequency of gout attacks.|
|2015-06||Tobacco control policy and incidence of respiratory infections and asthma in children.||This study examines whether the introduction of important tobacco control measures in the Netherlands is associated with a reduction in the number of diagnoses of respiratory infections and wheezing / asthma in children in general practice.|
|2015-12||The use of third-choice pain medications by osteoarthritis patients in general practice.||Pain is a common problem in osteoarthritis. These pain complaints are often treated conservatively by the GP. Adequate pain relief is often not achieved with paracetamol and NSAIDs. The doctor can then take various follow-up steps. This IPCI study examines how often various follow-up steps, namely opiates, corticosteroid injections and amitriptyline, are prescribed and in what order. Furthermore, it will be investigated whether there are changes over time. It will also be examined which (patient) characteristics are associated with the prescription of this medication. In addition, it will be investigated how long patients use them for opiates.|
|2015-13||The use of amitriptyline for musculoskeletal complaints in general practice.||This study will investigate how often amitriptyline is prescribed and for which musculoskeletal complaints this is mainly done.|
|2016-06||Laboratory tests in children in primary care.||The reason, frequency, and composition of laboratory tests ordered in children in primary care is not known. There might be overuse of laboratory testing (for example in fatigue) and underuse of laboratory testing (for example in screening for elevated glucose levels in obese children >= 10 year). Research into current clinical practice with regard to laboratory testing in children in primary care is lacking. The objective of the current observational study is to unravel this current practice using the IPCI database.|
|2016-07||Management of childhood asthma in primary care and safety of inhaled corticosteroids.||According to the existing asthma guidelines, children with asthma are treated according to a step-by-step plan. Men start using a short-acting bronchodilator. If this is not enough, an inhaled corticosteroid (ICS) will be started and the dose will either be increased or a long-acting bronchodilator will be added. Once the respiratory complaints are under control, the guidelines recommend halving the dose of ICS after 3 months of therapy (step-down therapy). Based on epidemiological research, the researcher wants to map the therapy pattern of children with asthma with a focus on step-down therapy. The researcher also wants to investigate how often asthma remission occurs.|
|2016-09||Treatment pathway analysis: An evaluation of treatment patterns and drug utilization amongst incident dementia cases in Electronic Health Records databases.||The rich and diverse collection of healthcare data sources available in the European Medical Information Framework (EMIF) presents an unprecedented opportunity to study patterns of drug usage. An objective of EMIF is to enable researchers to use Electronic Health Record (EHR) data to analyze treatment patterns in a specific population through an end user application providing a platform for future treatment pathway analysis within EMIF. More specifically, this study will utilize EHR data to investigate patterns of drug treatment in incident cases of dementia, and also, if feasible, in a subset of these patients with clinically diagnosed Alzheimer's disease.|
|2017-01||Clinical prediction rules for appendicitis in young patients in primary care.||In this study the reseacher investigates the validity of seven existing clinical decision rules for appendicitis in children with acute abdominal pain in primary care. Also is evaluated whether the use of the CRP test, in addition to these decision rules, has added diagnostic value.|
|2017-02||Proof of concept study for large-scale patient-level predictive modelling in the OHDSI data network: a case study on depression.||The objective of this large-scale patient-level predictive modelling study is to develop models using 5 commonly used classifiers for a single at risk cohort (pharmaceutically treated depression cohort) and 22 outcome cohorts.|
|2017-03||Investigating Birth Month-Disease Risk Relationships Across the OHDSI Network.||Derive data on birth month-disease risk relationships from large healthcare organizations/hospitals and healthcare facilities across the United States of America and throughout the world. Integrative analysis will be performed using established climate models, and knowledge of environmental factors that vary by season and climate.|
|2017-04||Comparative effectiveness of alendronate and raloxifene in reducing the risk of hip fracture.||Osteoporosis is characterized by decreased bone mass and deterioration of bone tissue, resulting in reduced bone strength and increased fracture risk. Alendronate and raloxifene are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. This study aims to compare the effectiveness in reducing the risk of hip fracture between alendronate and raloxifene and to evaluate the adverse reactions of both medications.|
|2017-05||Prevalence of disabling spasticity in stroke patients in the Netherlands.||The aim of this study is to determine the prevalence of bothersome spasticity in a large group of stroke patients by determining the use of drug therapy in stroke patients.|
|2017-06||Determinants of Metoprolol prescribing.||In this study the researcher studies within the IPCI database whether new female starters on metoprolol are dosed differently than men, or stop earlier due to side effects.|
|2017-07||Prescription of methylphenidate in adults and associated adverse reactions.||This study studies the determinants associated with the prescription of methylphenidate in adults. In addition, it is investigated which determinants are associated with the occurrence of severe cardiovascular and psychiatric endpoints in adult users of methylphenidate / other amphetamines.|
|2017-08||Prevalence of hypoglycaemia in patients treated with a sulphonurea for diabetes mellitus type 2.||In this study, the researcher wants to determine the rate of hypoglycaemia in patients treated with a sulphonurea (SU) derivative, called glimepiride and gliclazide.|
|2017-09||Adherence to the guidelines of the NHG (Dutch General Practitioners association) for the diagnosis of hypertension in primary care.||The diagnosis of hypertension must be based on multiple consultation room measurements on several days, a 30-minute method or an ambulatory 24-hour measurement. Diagnoses made on a one-off measurement can lead to over- and under-treatment. The researcher studies the extent to which the criteria for diagnosing hypertension in primary care are met. It is also being studied whether there has been an improvement in the quality of the diagnosis of hypertension in the last 10 years since the publication of the 2006 standard.|
|2017-10||High blood eosinophil levels as independent risk factor of severe asthma exacerbations and mortality in adult patients with asthma.||By means of a retrospective cohort study in multiple European Electronic Primary Care databases, including IPCI, the researchers want to study the effect of blood eosinophils as risk factor of severe asthma exacerbations and mortality in adult patients with asthma.|
|2017-12||Investigating the relationship in paediatric population between antibiotics dosing of antibiotics (prescribed, dispensed or administered) and patient's weight.||In this study the researchers would like to assess in European Medical Information Framework (EMIF) Electronic Healthcare Records (EHR) databases (DBs) the relationship between dosing of antibiotics prescribed, administered or dispensed (either for outpatients or inpatient settings) to children (age 0-18 yr), and their weight, age and height.|
|2017-14||Proof of concept study for large-scale patient-level predictive modelling in the OHDSI data network: a case study on patients with diabetes.||The objective of this large-scale patient-level predictive modelling study is to develop models using 5 commonly used classifiers for two at risk cohorts (Type 1 Diabetes,Type 2 Diabetes) to predict Cardiovascular Disease (CVD) outcomes. The study is implemented across the OHDSI collaborator network to externally validate the models and assess their transportability across databases from a number of countries.|
|2018-01||Chronic inflammatory demyelinating polyneuropathy (CIDP): incidence, prevalence and medical care in the Netherlands.||In this study, the researcher in the IPCI cohort wants to determine the incidence and prevalence of CIDP and to map the current diagnosis and treatment of CIDP.|
|2018-02||Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study.||The researcher want to study at first: the association between the use of oral bisphosphonates and the progression (stage worsening or entering renal replacement therapy/transplant) of kidney disease. Secondly: the relationship between oral bisphosphonate use and incident symptomatic fractures. Thirdly: the risk of adverse events (upper gastro-intestinal events, hypocalcemia/hypophosphatemia, or acute kidney injury) amongst users of oral bisphosphonates, compared to matched non-users.|
|2018-06||Incidence, prevalence and determinants of chronic cough in primary care.||By means of retrospective cohort study, the researchers want to investigate the following: (1) incidence and prevalence of chronic cough; (2) determinants of chronic cough with regard to lifestyle factors, comorbidity, drug use and (3) treatment of chronic cough in primary care.|
|2019-01vs2||Investigation of the link between allergies and metabolic diseases during different lifespan stages.||Both metabolic diseases and atopic disorders have been increasing worldwide, particularly in westernized countries. In most living multi-cellular organisms, metabolic homeostasis and the immune system influence each other in multiple manners. New insight into the possible link between atopy and metabolic disorders may provide clues for new treatment possibilities. The researchers are aiming to investigate this potential link with data from IPCI and Kinderhaven (an outpatient clinic of Erasmus MC).|
|2019-02||Drug utilization studies using IPCI mapped to a Common Data Model: an EHDEN proof of concept study assessing respiratory drug use in patients with asthma or COPD.||The European Health Data and Evidence Network (EHDEN) project is an international project supported by the Innovative Medicines Initiative (IMI) aiming to standardize health care data to a common data model (OMOP) and to develop and implement tools to facilitate research on large electronic health care databases. To investigate the validity and functionality of this approach, the researchers want to conduct a drug-utilisation study using IPCI mapped to a common data model. As first proof of concept study the researchers want to investigate characteristics of respiratory drug use in patients with asthma and chronic obstructive pulmonary disease (COPD) which are both prevalent conditions and primarily treated by GPs. By means of a drug utilisation study the researchers want to investigate i) the frequency of use (incidence and prevalence), ii) characteristics of patients initiating treatment with respiratory drugs, iii) treatment patterns and changes over time and iv) treatment adherence. In addition the researchers want to investigate whether the results of this study are consistent with the data as obtained when using the standard IPCI data (thus not mapped to the common data model).|
|2019-03||Evaluating the EHDEN tools for assessing safety signals identified by the Uppsala Monitoring Centre (WHO) using IPCI mapped to a Common Data Model: proof of concept study assessing Denosumab (risk of vasculitis) and Ceftriaxone (risk of hepatitis).||This is a proof-of-concept study evaluating EHDEN tools for post marketing drug safety surveillance (pharmacovigilance) with specific objectives: 1. to analyze previously identified signals by the Uppsala Monitoring Centre: the association between subcutaneous Denosumab use and the risk of vasculitis and the association between Ceftriaxone use and the risk of hepatitis in patients aged 75 years or older. 2. to develop prediction tools for the risk of these adverse drug reactions amongst users of these same drugs. 3. to detect new safety signals in iterative analyses of VigiBase (in 2020-2022), and to repeat steps 1 to 2 to expand the knowledge regarding the association between drug-ADR combinations detected and evaluate the possibility to confirm/reject them through IPCI data via the EHDEN tools.|
|2019-04||Identifying resource use associated with exacerbations and routine care of COPD.||The open-source Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) enables the systematic analysis of different observational databases by giving them a common structure and coding. The European Health Data & Evidence Network (EHDEN) project looks to extend the use of the OMOP-CDM across Europe and understand its usefulness for regulatory and HTA purposes. In this study the researchers seek to understand the usefulness of the OMOP-CDM for HTA using COPD as a case study. They aim to do this by comparing estimates of various parameters including COPD exacerbations and healthcare resource utilisation on routinely collected primary care data in the Netherlands (i.e. IPCI) and on a version of IPCI that has been mapped to the OMOP-CDM.|
|2019-06||Knee and hip osteoarthritis: prevalence, incidence, X-ray use, and referrals.||The first part of this study will describe the prevalence and incidence of knee and hip osteoarthritis under different ICPC codes. Also, an estimate will be made of the future trend of knee and hip osteoarthritis in the Netherlands until 2040. In addition, it will be investigated whether there are changes over time in the use of X-rays in general practice for knee and hip osteoarthritis after the introduction of the recommendation of the NHG standard to no longer use X-rays as a diagnostic tool. Finally, the current policy of GPs regarding referrals of patients with knee and hip osteoarthritis to secondary care orthopedics will be mapped out. This information will provide an indication of compliance with current guidelines regarding referral to secondary care by general practitioners in the Netherlands.|
|2019-07||Does pregnancy affect the risk of severe asthma exacerbations?||Data from literature suggests that the incidence of severe asthma exacerbations increases during pregnancy but information from the Netherlands is lacking. To study the incidence of severe asthma exacerbations prior; during and post-pregnancy, as well as to investigate risk factors of severe asthma exacerbations and to investigate asthma treatment patterns, this retrospective cohort study will be conducted within the IPCI database.|
|2019-08||Association between blood eosinophils and cancer in a real world setting.||Pathophysiologic data suggest that (blood and mucosal) eosinophils may protect against cancer, but data are conflicting and the role of eosinophils and their mediators could be cancer type dependent. As incidental finding in a previous study on high blood eosinophils levels and risk of severe asthma exacerbations, the researchers observed that the prevalence of cancer was higher in patients with low blood eosinophil counts (300 cells/uL) and that high blood eosinophils protected against mortality. This case-control study is to further explore the association between blood eosinophils and cancer as well as mortality in the general population.|
|2019-09||The actual use of codes (SNOMED, RxNORM Extended and LOINC) in various observational databases and consequences for cohort definitions.||This study aims to investigate the concept usage patterns across different datasets and their impact on cohort identification to facilitate cross-institutional and network studies. For every standard concept in the OMOP CDM, the researchers will investigate if it is used at each site, and if used, which source code(s) are used at individual sites, and how differences in corresponding source codes impact the portability of cohort identification algorithms.|
|2019-10||Effectiveness of topical corticosteroids in children with atopic eczema in general practice.||The advice of the NHG standard eczema is to treat atopic eczema with a step-by-step strategy using topical corticosteroids. The current advice is to start with a class I corticosteroid for moderate eczema. However, starting with a more potent corticosteroid may lead to a faster recovery and thus fewer consultations and referrals than with a class I corticosteroid. The researchers want to investigate which treatment GPs initially start for children with atopic eczema and determine the relationship between this strategy and consultations or referral in general practice.|
|2019-11||Comorbidities in osteoarthritis.||This research aims to examine:  prevalence and incidence of comorbidities in osteoarthritis and time sequence between osteoarthritis and comorbidities;  common clusters and impact of comorbidities in people with osteoarthritis;  association between commonly used osteoarthritis analgesics and comorbidities; and  consistency of osteoarthritis comorbidity patterns across countries. Four national/regional registration databases in the UK, Netherlands (IPCI database), Sweden and Spain will be used for aim 1-3. Finally data from different countries will be meta-analyzed (aim 4) for consistency between countries.|
|2019-12||Utilisation and comparative safety of disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: a multi-database real-world cohort study.||In this study the researchers first of all aim to characterize treatment patterns in patients newly diagnosed with rheumatoid arthritis in a drug utilization study. Secondly, they look at the comparative risk of serious adverse events such as infection, cancer and cardiovascular outcomes according to conventional synthetic disease modifying anti-rheumatic drugs used in a comparative safety study. Finally, the researchers aim to predict all the outcomes above separately for newly diagnosed rheumatoid arthritis patients in a prediction study.|
|2019-13||Ranitidine and other histamine H2 receptor antagonists - a drug utilisation study.||Ranitidine is a competitive and reversible inhibitor of the action of histamine and indicated for the management of peptic ulceration, Gastro-Esophageal Reflux Disease (GERD), reflux oesophagitis and Zollinger-Ellison syndrome. Results of a preliminary laboratory analysis have shown the presence of N-Nitrosodimethylamine (NDMA), a human carcinogen, in ranitidine. At the request of the European Commission, the EMA's Committee for Medicinal Products for Human Use (CHMP) is collecting and evaluating data on ranitidine (and use of other H2 receptor antagonists) in Europe. This data should allow the EMA to assess how many patients have been exposed to ranitidine and thus potentially at risk of NDMA and whether a regulatory action to protect patients and public health at the EU level is warranted. With this drug utilisation study the researchers aim to determine drug utilisation and prescription patterns of medicinal products containing H2-receptor antagonists. These data will give insight on the number of patients using ranitidine and potentially at risk of NDMA.|
|2020-01||European non-interventional post-authorization safety study (PASS) related to serious cardiovascular (CV) events of myocardial infarction (MI) and stroke, and all-cause mortality for romosozumab.||This is a European non-interventional post-authorization safety study (PASS) to evaluate the risk of serious CV events of MI and stroke, and all-cause mortality including CV death associated with the use of romosozumab in routine clinical practice compared with other available osteoporosis (OP) medications.|
|2020-02||European non-interventional post-authorization safety study related to Serious Infections (SI) for romosozumab.||This is a European non-interventional post-authorization safety study (PASS) to evaluate the risk of SIs associated with the use of romosozumab in routine clinical practice compared with other available osteoporosis (OP) medications.|
|2020-03||European non-interventional post-authorization safety study (PASS) related to adherence to the risk minimization measures for romosozumab by the EU-ADR Alliance.||The aim of this drug utilization PASS (post-authorization safety study) is to evaluate adherence to the cardiovascular Risk Minimalization Measures (RMMs) for the use of romosozumab in routine clinical practice in seven European countries.|
|2020-04||Incidence, prevalence and treatment of COVID-19.||The researchers want to visualize the COVID epidemic and to use historical data to determine whether any potential candidates (e.g. hydroxychloroquine) for reuse have shown an effect on viral infections in the past.|
|2020-05||Hip fracture - global secular trends in incidence and post-fracture treatment and mortality; a multi-country, observational study based upon population-based health records.||This is a study of secular trends in hip fracture for incidence, mortality, and use of post-fracture treatment using a standardized methodology applied to electronica health record databases spread across Asia, Oceania, North and South America, Western and Northern Europe.|
|2020-06||High dose ICS+LABA vs. Medium dose ICS+LABA+LAMA in patients with uncontrolled severe asthma - Characteristics of treatment response.||With this Retrospective Cohort Study, the researchers aim to explore patient characteristics of treatment response of patients with uncontrolled severe asthma to one of the following treatment categories: (1) high dose ICS+LABA, (2) medium dose ICS+LABA+LAMA and (3) high dose ICS+LABA+LAMA using real life data from 4 electronic health care databases from Europe: the Netherlands (IPCI), Denmark (Aarhus), Italy (HSD) and UK (CPRD). The researchers aim to investigate drivers of response to any of the three treatment options and to investigate the patient phenotype that best characterises this response.|
|2020-07||Gout in general practice; risk factors and treatment (addition to the research 2015/03).||In this study the researchers investigate whether the presence of gout is associated with future renal or cardiovascular morbidity and whether maintenance treatment with allopurinol reduces this risk.|
|2020-08vs2||At 24H-ABPM, are the nocturnal systolytic blood pressure values necessary for CVE risk assessment?||With the 24 hour blood pressure measurements it is known that the mean nocturnal values __can differ from the day values. In the category of non-dippers, which means that the nocturnal values __do not fall sufficiently by 10%, this is used as a risk predictor. The non-dipping category is an independent risk for developing a cardio vascular event (CVE). In the Netherlands, the SCORE model is used to determine CVE risk (SCORE: Systematic Coronary Risk Evaluation, a European cohort study calculating the risk of CVE at a 10-year follow-up) looking at gender, smoking, tension, lipids aged 40-70 years. The researchers investigate what the nocturnal values __add to the risk assessment for developing CVE and if we need the nocturnal values __if we use the SCORE model.|
|2020-09||Patient-level predictive modelling in the OHDSI data network: predicting (a) hospital admission and (b) death.||The objective of this large-scale patient-level predictive modelling study is to develop models using multiple commonly used algorithms to predict for each visit of the patient to the general practitioner (a) hospital admission in the next 30, 60, and 90 days and (b) death in the next 30, 60 and 90 days. The classifiers will be trained on two distinct data sets. The first data set will constitute coded data only (that is, ICPC diagnosis, laboratory tests, etc.), and the second set will add free text. The researchers want to (a) assess whether they can predict hospital admissions and death, and (b) assess whether adding free text to coded data will improve the predictions. In a later stage, the study will be implemented across the OHDSI collaborator network to externally validate the models and assess their transportability across databases from a number of countries.|
|2020-10||Predicting and Recalibrating Outcomes Toward External Understanding Study (PROTEUS): a proof of concept for a cardiovascular clinical prediction model.||The objective of this large-scale patient-level predictive modelling study is to build new prediction models and externally validate an existing cardiovascular clinical prediction models (CPM) routinely used in clinical practice: the Pooled Cohort Equations. The Pooled Cohort Equations predict 10-year risk of atherosclerotic cardiovascular disease among adults without pre-existing cardiovascular disease. In this study, the researchers will collaborate with data partners to implement this existing prediction model against the OMOP Common Data Model using the OHDSI PatientLevelPrediction package. They will then apply the package across the participating data partners in the OHDSI community to characterize the target populations and estimate their baseline risk. Furthermore, the researchers will externally validate the performance of the models in real-world settings and determine the potential impact of recalibration on the model use in clinical practice.|
Overview of collaborative projects
European Health Data and Evidence Network (EHDEN)
Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health databases. These include structured data in the form of diagnoses, medications, laboratory test results, and unstructured data in clinical narratives. The Electronic Health Data in a European Network (EHDEN) Consortium leverages these vast volumes of data to improve future clinical practice and individual patient outcomes by increasing our understanding of disease and treatment pathways. EHDEN will galvanize transparent and reproducible analytics that will generate valid real-world evidence to improve patient care, and enable medical outcomes-based research at an unprecedented scale. The EHDEN Consortium provides the infrastructure and eco-system supporting disease-specific projects in the IMI Big Data for Better Outcomes (BD4BO) programme. The core of EHDEN is the use of a common data model (OMOP-CDM), standardised outcome assessment (ICHOM), and transparent open-source analytics (OHDSI). The objective of the EHDEN consortium is to provide all the necessary services that enable a distributed European data network to perform fast, scalable and highly reproducible research, while respecting privacy regulations, local data provenance and governance. This will include services and tools to perform data standardization, analytical pipelines, tools to share study results, and tools for stakeholder engagement and training. The EHDEN Consortium combines active participation of stakeholder representatives with proven experience in: a) integrating different data types, methods and technologies to utilize diverse clinical datasets; b) platform development to make methods and datasets Findable, Accessible, Interoperable and Reusable (FAIR); and c) engaging a wide variety of stakeholders, including health technology assessment agencies, regulators and patients.
IPCI is participating in multiple use cases in EHDEN.
European COVID-19 Observational Research Exchange (ECORE)
In June 2020, EMA contracted the company IQVIA with a project to build a framework for the conduct of multicentre cohort studies on the use of medicines in COVID-19 patients (press release). This project will include the identification of large national cohorts of COVID-19 patients and appropriate comparator groups, the development of a study protocol template for multinational studies as well as the establishment of a collaborative framework for researchers. The project will be carried out in collaboration with the European Health Data & Evidence Network (EHDEN) consortium, which was established under the Innovative Medicines Initiative and includes the Erasmus Medical Centre in Rotterdam and the University of Oxford as project lead and research coordinator, respectively.
The IPCI database is participating in a proof-of-concept study.
Ranitidine Drug Utilisation Study
Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach. It is indicated for the management of peptic ulceration, Gastroesophageal Reflux Disease (GERD), reflux oesophagitis, Zollinger-Ellison syndrome, chronic episodic dyspepsia, peptic ulcer hemorrhage, prophylaxis of stress ulceration, Mendelsons syndrome, duodenal ulcers, benign gastric ulcers, post-operative ulcer, symptomatic relief of heart burn, dyspepsia (acid indigestion), hyperacidity, and prevention of symptoms associated with consuming food and drink. Ranitidine is available for oral and parenteral administration.
The EU authorities were notified of the results of a preliminary laboratory analysis of ranitidine showing the presence of N-Nitrosodimethylamine (NDMA). The results on a limited sample of products showed that for the majority of both ranitidine APIs and finished products, NDMA was above the acceptable intake established during the referral procedure under Article 31 of Directive 2001/83/EC for sartans with a tetrazole ring (considering the maximum daily dose authorised in the EU, and long-term use in a 50 kg adult). Following extensive validation of the analytical method, the presence of NDMA in ranitidine finished products was confirmed.
The objective of this project is to rapidly generate information about prescribing and use patterns of ranitidine-containing medicines in EU Member States that will inform on the population at risk of exposure to NDMA (or other nitrosamines) through use of ranitidine.
The OMOP-CDM process applied in this study has been been presented at a workshop organised by the EMA at the ICPE conference (more information)
An international cohort of OHDSI collaborators obtained a grant from the COVID-19 Therapeutics Accelerator to lead an effort to compare the effectiveness of treatments, including corticosteroids such as dexamethasone, under current evaluation for COVID-19 across an international observational data network. The Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments.
Researchers from the University of Oxford, Columbia University, UCLA and Erasmus University Medical Center are leading this work through Project SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses), one of the emerging efforts to come from OHDSI’s global work surrounding COVID-19 research.
The IPCI Database is used in this study.
OHDSI Network Studies
The Observational Health Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. OHDSI aims to generate accurate, reproducible, and well-calibrated evidence and promote better health decisions and better care. All our solutions are open-source. OHDSI has established an global network of researchers and observational health databases with a central coordinating center housed at Columbia University, see www.ohdsi.org.
IPCI is participating in many studies executed by the OHDSI community, including the work done on COVID-19 (link)